Heat made AZ's FluMist ineffective against swine flu; Diamyd begins diabetes jab trial;

> FluMist maker AstraZeneca ($AZN) blames heat for its vaccine's ineffectiveness against swine flu. Report

> Diamyd Medical has dosed the first patient in its Type 1 diabetes vaccine study. Release

> ACIP has recommended Merck's ($MRK) Gardasil 9 for females ages 9 to 26 and males ages 9 to 21. Release

> In a Phase I study, Themis Bioscience's Chikungunya vaccine candidate raised concentrations of neutralizing antibodies in three dose cohorts after one immunization. Release

> Targovax has appointed Øystein Soug as its new CFO. Release

And Finally... The CDC says flu vaccines were only 18% effective this season. Report (reg. req.)

Suggested Articles

With its phase 3 trial moving right along, Moderna is expecting efficacy data in November—likely after Pfizer and BioNTech, but before everyone else.

BioNTech expects a quick turnaround once the transaction closes and plans to produce up to 250 million doses of BNT162b2 in the first half of 2021.

Participation in clinical trials among Black people is low, FDA statistics show, even as drugmakers prioritize including them in COVID-19 shot trials.